The opioid crisis continues to plague the United States. While great strides have been made nationwide to decrease overprescribing, improvements are still needed to appropriately educate patients on the safe and responsible use, storage and disposal of opioids. Pain after surgery is often treated with opioid medications. Opioid medications can have side effects. Some side effects are relatively minor (constipation, nausea, vomiting), while others are more severe (sedation, abnormal breathing, etc.) and can lead to serious illness or death. Opioid pain medications when used the wrong way may also be addictive. Due to theses side effects, sometimes patients feel uncomfortable about taking these medications, and doctors prescribe them very cautiously. However, when used properly and safely, opioid pain medications are excellent pain relievers.
Addinex, a technology company, has developed a device to help patients take opioids more safely. In this study the investigators aim to enroll a total of 30 patients who undergo spine surgery. Half will be randomly assigned to receive a standard pill bottle with opioids at discharge and will download a mobile app so that they can record their daily pain scores and the number of opioids they take for two weeks after surgery. The other half will receive the new opioid dispenser filled with opioids and a mobile app that generates a passcode that opens that device only at designated times. For this group of patients, every time the patient wants to take an opioid, they need to go to the app, enter their pain score before the app generates a passcode. The investigators will be tracking all study patients' opioid use and pain scores for the two weeks after surgery, will count how many pills they have left over 14 days after their surgery during a live telehealth session, and ask patients how they liked using the device. Results from this study will help understand if the Addinex device could potentially be useful to patients in the future after surgeries as opposed to typical pill bottles.

开始日期2024-11-01

申办/合作机构

Hospital for Special Surgery

NCT06590402 / Not yet recruiting临床4期IIT

A Pilot Study Comparing Anterior Femoral Cutaneous Nerve Blocks to Adductor Canal Blocks in Pediatric Ambulatory Knee Surgeries

The goal of this pilot clinical trial is to compare anterior femoral cutaneous nerve block (AFCN) to adductor canal block ACB) for pediatric patients undergoing either anterior cruciate ligament (ACL) or medial patellofemoral ligament (MPFL). The aims of this trial are:
* To measure postoperative functional outcomes in patients who received AFCNB vs. ACB.
* To calculate postoperative opioid requirements in pediatric knee surgeries that received AFCNB vs. ACB.
* To calculate pain intensity levels at rest and with ambulation in patients who received AFCNB vs. ACB.
* To quantify sensory deficits in patients who received AFCNB vs. ACB.
Subjects undergoing ACL procedures will be compared between those who received the adductor canal block to those who received the anterior femoral cutaneous nerve block. The researchers will also compare individuals who underwent MPFL procedures and received an anterior femoral cutaneous nerve block with those who received the adductor canal block.
Participants will:
* Be randomized to receive either the AFCNB or ACB in addition to standard of care analgesia.
* Maintain a patient diary to document daily pain meds/pain scores
* Complete follow up surveys/questionnaires via telephone and during their office visits with surgeons.

开始日期2024-10-01

申办/合作机构

Hospital for Special Surgery

NCT06306157 / Enrolling by invitation临床4期IIT

Low Dose Naltrexone (LDN) Therapy for Complex Regional Pain Syndrome (CRPS): a Feasibility Study

Complex Regional Pain Syndrome (CRPS) is a rare and often debilitating chronic pain condition whereby individuals may experience extreme sensitivity, discoloration, and swelling of the affected area -- along with numerous other painful symptoms. There are currently a limited number of treatment options available to those suffering with the condition, with various treatments including nerve blocks, neuropathic medications, and desensitization physical therapy modules. There is budding interesting in the role naltrexone, an opiate antagonist, may play in the pain management of CRPS when prescribed in very low doses. This study aims to collect preliminary data on pain scores, symptom severity, and side-effects in patients with Complex Regional Pain Syndrome randomized to receive low dose naltrexone or placebo capsules. Enrollment of 40 patients total will occur over two years from study start to study end. Each patient will be randomized to receive placebo capsules or active low dose naltrexone capsules, with both the patient and treating clinician blind to the randomization. Each patient will be actively enrolled in the study for six months and will take the medication daily at the instructed dose for the respective duration of time. Following the initial visit and study enrollment, the investigators are asking each patient to return for three (3) in-person follow-up office visits. These office visits will occur 1 month after the patient starts the medication, 3 months afterwards, and 6 months afterwards. The final 6-month office visit will mark the conclusion of the patient's active participation in the study.

开始日期2024-10-01

申办/合作机构

Hospital for Special Surgery

100 项与 Hospital for Special Surgery 相关的临床结果

登录后查看更多信息

0 项与 Hospital for Special Surgery 相关的专利（医药）

登录后查看更多信息

14,742

项与 Hospital for Special Surgery 相关的文献（医药）

2024-12-01·Cellular and Molecular Life Sciences

iRhom2 regulates ectodomain shedding and surface expression of the major histocompatibility complex (MHC) class I

Article

作者: Bonelli, Simone ; Calligaris, Matteo ; Zito, Giovanni ; Lichtenthaler, Stefan F ; Miele, Monica ; D'apolito, Danilo ; Spanò, Donatella P ; Nuti, Elisa ; Carcione, Claudia ; Müller, Stephan A ; Blobel, Carl P ; Scilabra, Simone D ; Rossello, Armando ; Di Bella, Mariangela ; Amico, Giandomenico

AbstractProteolytic release of transmembrane proteins from the cell surface, the so called ectodomain shedding, is a key process in inflammation. Inactive rhomboid 2 (iRhom2) plays a crucial role in this context, in that it guides maturation and function of the sheddase ADAM17 (a disintegrin and metalloproteinase 17) in immune cells, and, ultimately, its ability to release inflammatory mediators such as tumor necrosis factor α (TNFα). Yet, the macrophage sheddome of iRhom2/ADAM17, which is the collection of substrates that are released by the proteolytic complex, is only partly known. In this study, we applied high-resolution proteomics to murine and human iRhom2-deficient macrophages for a systematic identification of substrates, and therefore functions, of the iRhom2/ADAM17 proteolytic complex. We found that iRhom2 loss suppressed the release of a group of transmembrane proteins, including known (e.g. CSF1R) and putative novel ADAM17 substrates. In the latter group, shedding of major histocompatibility complex class I molecules (MHC-I) was consistently reduced in both murine and human macrophages when iRhom2 was ablated. Intriguingly, it emerged that in addition to its shedding, iRhom2 could also control surface expression of MHC-I by an undefined mechanism. We have demonstrated the biological significance of this process by using an in vitro model of CD8+ T-cell (CTL) activation. In this model, iRhom2 loss and consequent reduction of MHC-I expression on the cell surface of an Epstein-Barr virus (EBV)-transformed lymphoblastoid cell line dampened activation of autologous CTLs and their cell-mediated cytotoxicity. Taken together, this study uncovers a new role for iRhom2 in controlling cell surface levels of MHC-I by a dual mechanism that involves regulation of their surface expression and ectodomain shedding.

2024-12-01·Bone

Psoas muscle cross sectional area relates to bone density and microarchitecture in candidates for spine fusion surgery

Article

作者: Raphael, Joseph ; Dash, Alexander ; Nieves, Jeri ; Kim, Han Jo ; Iyer, Sravisht ; D'Erasmo, Giavanna ; Song, Junho ; Billings, Emma ; Breighner, Ryan ; Stein, Emily ; Cunningham, Matthew ; Qureshi, Sheeraz

Prior studies demonstrate that muscle and bone health are integrally related, and both independently impact orthopedic surgery outcomes. However, relationships between bone density, in vivo microarchitecture, and muscle area have not been previously investigated in orthopedic surgery patients. This study assessed associations between psoas cross sectional area (CSA), bone mineral density (BMD), and microstructure in a cohort undergoing spine fusion. Pre-operatively, bilateral psoas CSA was measured on axial lumbar spine CT in the L3-L4 disc space. To adjust for body size, Psoas Muscle Index (PMI) was calculated (CSA divided by the square of patient height). High resolution peripheral quantitative CT (HR-pQCT, XtremeCT2) assessed volumetric BMD (vBMD), cortical (Ct) and trabecular (Tb) microarchitecture at the distal radius and tibia. Areal BMD (aBMD) was measured by DXA at the lumbar spine (LS), total hip (TH), femoral neck (FN), and the 1/3 radius (1/3R). Pearson correlations related psoas CSA and bone imaging parameters before and after correcting for height and weight. Among 88 patients included, mean age was 63 ± 12 years, BMI was 28 ± 7 kg/m², 47 (53 %) were female. Larger psoas CSA was associated with higher vBMD, greater Ct thickness and better Tb microarchitecture (higher Tb number and lower Tb separation) at the tibia and radius. Larger psoas CSA was also associated with greater aBMD at TH and FN bilaterally and 1/3R (r 0.33 to 0.61; p < 0.002 for all comparisons). Psoas CSA was not associated with aBMD at the LS. Similar results were observed when relating PMI, and adjusting for age, height and weight to HR-pQCT and DXA measurements. Investigation of subgroups by sex demonstrated that relationships were similar magnitude among women but not the men. Patients who underwent primary compared to revision spine surgery had similar associations. Our results demonstrate a link between psoas muscle size and peripheral bone microarchitecture among patients undergoing posterior lumbar spinal fusion. Given the importance of both muscle and skeletal integrity to the success of spine surgery, further study regarding the associations between measurements of psoas muscle, bone microarchitecture, and surgical outcomes is warranted.

2024-11-15·Spine

Perioperative Infection Prophylaxis With Vancomycin is a Significant Risk Factor for Deep Surgical Site Infection in Spine Surgery

Article

作者: Johnson, Mitchell ; Subramanian, Tejas ; Mok, Jung K ; Kazarian, Gregory S ; Kim, Han Jo ; Jordan, Yusef Y ; Hirase, Takashi ; Brause, Barry

Study Design.Retrospective cohort.Objective.The purpose of this study was to compare the efficacy of cefazolin versus vancomycin for perioperative infection prophylaxis.Summary of Background Data.The relative efficacy of cefazolin alternatives for perioperative infection prophylaxis is poorly understood.Materials and Methods.This study was a single-center multisurgeon retrospective review of all patients undergoing primary spine surgery from an institutional registry. Postoperative infection was defined by the combination of three criteria: irrigation and debridement within 3 months of the index procedure, clinical suspicion for infection, and positive intraoperative cultures. Microbiology records for all infections were reviewed to assess the infectious organism and organism susceptibilities. Univariate and multivariate analyses were performed.Results.A total of 10,122 patients met inclusion criteria. The overall incidence of infection was 0.78%, with an incidence of 0.73% in patients who received cefazolin and 2.03% in patients who received vancomycin (OR: 2.83, 95% CI: 1.35–5.91, P=0.004). Use of IV vancomycin (OR: 2.83, 95% CI: 1.35–5.91, P=0.006), BMI (MD: 1.56, 95% CI: 0.32–2.79, P=0.014), presence of a fusion (OR: 1.62, 95% CI: 1.04–2.52, P=0.033), and operative time (MD: 42.04, 95% CI: 16.88–67.21, P=0.001) were significant risk factors in the univariate analysis. In the multivariate analysis, only noncefazolin antibiotics (OR: 2.48, 95% CI: 1.18–5.22, P=0.017) and BMI (MD: 1.56, 95% CI: 0.32–2.79, P=0.026) remained significant independent risk factors. Neither IV antibiotic regimen nor topical vancomycin significantly impacted Gram type, organism type, or antibiotic resistance (P>0.05). The most common reason for antibiosis with vancomycin was a penicillin allergy (75.0%).Conclusions.Prophylactic antibiosis with IV vancomycin leads to a 2.5 times higher risk of infection compared with IV cefazolin in primary spine surgery. We recommend the routine use of IV cefazolin for infection prophylaxis, and caution against the elective use of alternative regimens like IV vancomycin unless clinically warranted.

项与 Hospital for Special Surgery 相关的新闻（医药）

2024-10-18

·PRNewswire

HSS Researchers Find CPAP Use Before Total Hip and Knee Replacement Surgery Reduces Risk of Emergency Department Visits After Surgery for Patients With Obstructive Sleep Apnea

PHILADELPHIA, Oct. 18, 2024 /PRNewswire/ -- In a study conducted at Hospital for Special Surgery (HSS), researchers found that patients with obstructive sleep apnea (OSA) who used continuous positive airway pressure (CPAP) therapy before total hip and knee replacement surgery significantly reduced their risk for complications after surgery compared with OSA patients who did not use CPAP therapy before surgery. The use of CPAP before surgery reduced the risk to the point where there was no difference in emergency department visit rates between patients with OSA and those without. These findings were presented at the Society of Anesthesia and Sleep Medicine (SASM) 14th annual meeting.1 "Obstructive sleep apnea affects 40 million adults in the United States and is associated with an increased complication risk among patients undergoing surgery," said Stavros Memtsoudis, MD, PhD, Anesthesiologist-in-Chief and Chair of the HSS Department of Anesthesiology, Critical Care & Pain Management. "Guidelines on the perioperative management of OSA patients undergoing surgery are backed by limited evidence. Current recommendations include preoperative screening for OSA and preoperative initiation of CPAP therapy. However, it remains unclear how often this recommendation is followed and how much it reduces complication risks." This information is especially important as healthcare systems shift from inpatient to outpatient hip and knee replacement surgery, where patients cannot be monitored as closely for perioperative complications. To evaluate whether CPAP use among OSA patients prior to surgery led to improved outcomes compared with those patients who did not use CPAP, the researchers extracted more than 100,000 cases of outpatient hip and knee replacement surgeries performed between 2018 and 2022 from the Merative MarketScan national claims data (representing patients and their dependents with employer-sponsored healthcare coverage). The primary outcome of interest was a visit to the emergency department within one day post-discharge, which acted as a stand-in to represent post-discharge complications. The researchers conducted three comparisons: 1) patients with OSA who used a CPAP machine before surgery, compared with patients who did not; 2) patients with OSA who did not use a CPAP machine before surgery, compared with patients without OSA; and 3) patients with OSA who used CPAP before surgery, compared with patients without OSA. The researchers found that OSA patients who underwent CPAP therapy before hip and knee replacement surgery (19% of 123,349 total hip/knee procedures studied) experienced fewer emergency department visits within one day after discharge compared with OSA patients who did not receive CPAP therapy before surgery. In addition, pre-surgical CPAP use in patients with OSA lowered their risk for complications to a similar level as patients without OSA. "These findings are significant as they support the notion that adhering to these guidelines can benefit OSA patients undergoing surgery," said Jashvant Poeran, MD, PhD, Director of Research in the HSS Department of Anesthesiology, Critical Care & Pain Management. "While we had anticipated these results based on the guidelines, this is the first study to demonstrate this on such a large scale." This study offers key insights for both patients and clinicians on ways to reduce the risk of complications after surgery. "It informs patients with OSA to engage in conversations with their perioperative physicians about strategies to lower their complication risk, including the preoperative initiation of CPAP therapy," said Dr. Poeran. "Additionally, this research highlights the advantages of preoperative initiation of CPAP therapy. We believe that this study strengthens the evidence supporting the benefits of preoperative CPAP therapy and will encourage both patients and clinicians to consider its increased use." While further validation of these findings is necessary, particularly in other surgical cohorts such as elective general surgery, these findings represent a significant advancement in recognizing the benefits of preoperative initiation of CPAP therapy. "These findings could influence care by emphasizing the importance of preoperative identification of OSA patients who are scheduled for surgery and subsequent initiation of CPAP therapy," Dr. Poeran said. In addition to replicating these findings in other surgical cohorts, future research should also examine subgroups of patients in which preoperative CPAP therapy may be even more beneficial. "These subgroups might include patients with multiple risk factors, such as OSA and obesity or other chronic conditions, as well as those with varying needs for opioid management." "Follow-up studies could investigate looking at other recommendations outlined in the guidelines such as preoperative screening for OSA and enhanced monitoring. This increased monitoring is crucial as hospital stays shorten and more and more surgeries are performed in an outpatient setting without an overnight stay and the subsequent opportunity to monitor these patients," Dr. Poeran concluded. Reference 1. Jashvant Poeran MD PhD, Haoyan Zhong MPA, Alex Illescas MPH, Lisa Reisinger MD, Crispiana Cozowicz MD, Periklis Giannakis MD, Jiabin Liu MD PhD, Stavros G. Memtsoudis MD PhD MBA. "Preoperative CPAP Use is Associated with Improved Outcomes in Patients with Obstructive Sleep Apnea Undergoing Orthopedic Surgery." Presented at: Society of Anesthesia and Sleep Medicine (SASM) 14th Annual Meeting, October 18, 2024; Philadelphia, PA. About HSS HSS is the world's leading academic medical center focused on musculoskeletal health. At its core is Hospital for Special Surgery, nationally ranked No. 1 in orthopedics (for the 15th consecutive year), No. 3 in rheumatology by U.S. News & World Report (2024-2025), and the best pediatric orthopedic hospital in NY, NJ and CT by U.S. News & World Report "Best Children's Hospitals" list (2024-2025). In a survey of medical professionals in more than 20 countries by Newsweek, HSS is ranked world #1 in orthopedics for a fifth consecutive year (2025). Founded in 1863, the Hospital has the lowest readmission rates in the nation for orthopedics, and among the lowest infection and complication rates. HSS was the first in New York State to receive Magnet Recognition for Excellence in Nursing Service from the American Nurses Credentialing Center five consecutive times. An affiliate of Weill Cornell Medical College, HSS has a main campus in New York City and facilities in New Jersey, Connecticut and in the Long Island and Westchester County regions of New York State, as well as in Florida. In addition to patient care, HSS leads the field in research, innovation and education. The HSS Research Institute comprises 20 laboratories and 300 staff members focused on leading the advancement of musculoskeletal health through prevention of degeneration, tissue repair and tissue regeneration. In addition, more than 200 HSS clinical investigators are working to improve patient outcomes through better ways to prevent, diagnose, and treat orthopedic, rheumatic and musculoskeletal diseases. The HSS Innovation Institute works to realize the potential of new drugs, therapeutics and devices. The HSS Education Institute is a trusted leader in advancing musculoskeletal knowledge and research for physicians, nurses, allied health professionals, academic trainees, and consumers in more than 165 countries. The institution is collaborating with medical centers and other organizations to advance the quality and value of musculoskeletal care and to make world-class HSS care more widely accessible nationally and internationally. . SOURCE Hospital for Special Surgery WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床结果

2024-10-03

·PRNewswire

OrthAlign Receives FDA 510(k) Clearance for Lantern® Hip

IRVINE, Calif., Oct. 3, 2024 /PRNewswire/ -- OrthAlign, Inc., a privately held medical device company, announces FDA 510(k) clearance of their Lantern Hip handheld technology for direct anterior total hip arthroplasty with the patient in the supine position. Lantern Hip is the latest addition to the Lantern platform, joining existing applications for total knee, revision knee, and partial knee arthroplasty. Continue Reading Lantern® Hip Lantern Hip builds upon the legacy of HipAlign® with enhanced technology and usability. Next-generation accelerometers and gyroscopes offer orthopedic surgeons a streamlined workflow, real-time navigation for cup positioning, and restoration of leg length and offset. The technology enables individualized cup positioning compared across multiple planes, including the functional pelvic plane, anterior pelvic plane, and coronal plane, with live pelvic tracking. Designed for personalized patient care, Lantern Hip eliminates the need for pre-operative imaging or capital equipment and is compatible with most implant systems, making it an ideal choice for the ASC setting. "Technologies like Lantern Hip represent the future of orthopedic surgery," said Edwin Su, MD, orthopedic surgeon at the Hospital for Special Surgery in New York, NY. "The system provides the information I need to accurately position each patient's hip components based on their unique anatomy, and I can hit the leg length and offset targets I want to achieve. These advancements, coupled with the new ability to place the cup in relation to the functional pelvic plane, hold the potential to greatly improve patient outcomes." "Adding the total hip application to the Lantern platform is an enhancement that not only broadens our capabilities, but also reinforces our commitment to providing innovative solutions," said Eric Timko, Chairman and CEO of OrthAlign. "As technology becomes the standard of care in total joint replacement, it's essential to deliver solutions that are clinically, operationally, and economically efficient. Lantern Knee and Balance have been a great success for OrthAlign and now, with Lantern Hip, surgeons can confidently and easily take technology to any site of service for their total hip replacements. I applaud our internal team and surgeon advisors for the countless hours spent developing a product that we expect will make a positive impact on healthcare." Lantern Hip will be on display at the American Association of Hip and Knee Surgeons (AAHKS) annual meeting in Grapevine, TX in November. To learn more, contact [email protected]. About OrthAlign, Inc. OrthAlign is a medical device company with a focus on delivering practical, cutting-edge technologies for orthopedic surgery. With a commitment to innovation and excellence, OrthAlign provides surgeons with user-friendly, cost-effective solutions to help improve patient care in joint replacement. In 2023, the company celebrated a record-breaking year with over $50 million in global revenue, reflecting its dedication to growth and leadership in the industry. Driven by the belief that everyone deserves exceptional healthcare, we are committed to making empowering technologies accessible to all. For more information regarding OrthAlign, please visit . HIPALIGN®, LANTERN®, and ORTHALIGN® are registered trademarks of OrthAlign, Inc. SOURCE OrthAlign WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

2024-09-30

·PRNewswire

HSS Orthopedics with Stamford Health Opens Westport CT Outpatient Center

New Facility Expands the Footprint of HSS and Stamford Health Collaboration WESTPORT, Conn., Sept. 30, 2024 /PRNewswire/ -- Hospital for Special Surgery (HSS), the world's leading academic medical center focused on musculoskeletal health, and Stamford Health, an award-winning independent, non-profit healthcare system today announced the opening of HSS Orthopedics with Stamford Health – Westport. The nearly 10,000-square-foot new regional outpatient center (OPC) in Westport, Connecticut, expands the Fairfield County footprint of the HSS and Stamford Health collaboration, established in 2016. Continue Reading Samuel Taylor, MD (sports medicine surgeon and Medical Director of HSS Orthopedics with Stamford Health - Westport), Kathleen Silard (President and CEO of Stamford Health), Jennifer Tooker (First Selectwoman of Westport), Elizabeth Longmore (SVP, COO at Stamford Health), Mary Cassai (EVP, Enterprise COO at HSS), Justin Oppenheimer (EVP, Chief Strategy, Growth, & Transformation at HSS), Andrea Moore (Second Selectwoman of Westport) The OPC is the second HSS and Stamford Health collaboration to come to the Westport area since the opening of HSS Sports Rehab-Westport in 2022. Additional physician office locations and sports rehabilitation facilities are located in Stamford, Greenwich, New Canaan, Wilton, Norwalk and Hamden, CT. "We're really excited to build on the commitment we've made alongside Stamford Health to enhance orthopedic care options to the residents of Westport and surrounding areas," said Samuel A. Taylor, MD, sports medicine surgeon and medical director of the OPC. "Patients now have increased access to world-class orthopedic care across a broad range of services." The Westport OPC features seven provider offices, 12 exam rooms, and two x-ray suites with services provided by Stamford Health Radiology. Highly specialized physicians and staff will offer care in hand and upper extremities, joint replacement, physiatry, spine, and sports medicine (surgical and non-surgical). Later this fall, the foot and ankle service will be available. Additionally, the center will launch HSS Orthopedics Now, becoming the second location in Connecticut to provide patients 12 years and older with quicker access to orthopedic care for sudden injuries and pain. "Westport has proven to be a terrific community in which to share our unparalleled expertise in musculoskeletal health," says Bryan T. Kelly, MD, MBA, president and CEO of HSS. "We're eager to expand our offerings in the Fairfield County community in partnership with Stamford Health and as part of HSS's wider growth plan across the entire tri-state region." Home to more than 25,000 residents, the town of Westport also has an intriguing historical connection to HSS as the birthplace of HSS's third Surgeon-in-Chief, William B. Coley, MD. One of the town's notable early families, the Coleys were prominent farmers and commercial shippers for 200 years. William Coley was born in 1862 in the Saugatuck neighborhood. The Coleytown section of Westport was named after the family. "We are incredibly proud of our collaboration with HSS and the orthopedic care we deliver to patients," said Kathleen Silard, president and CEO at Stamford Health. "Partnering with organizations like HSS allows us to bring world-class care to the communities we serve, close to home." The Westport OPC is located at 276 Post Road West and will operate Monday through Friday from 8:00am to 5:00pm. For more information or to schedule an appointment, visit hss.edu/hss-orthopedics-stamford-health-westport.asp or contact the center directly at (203) 391-2270. About HSS HSS is the world's leading academic medical center focused on musculoskeletal health. At its core is Hospital for Special Surgery, nationally ranked No. 1 in orthopedics (for the 15th consecutive year), No. 3 in rheumatology by U.S. News & World Report (2024-2025), and the best pediatric orthopedic hospital in NY, NJ and CT by U.S. News & World Report "Best Children's Hospitals" list (2023-2024). In a survey of medical professionals in more than 20 countries by Newsweek, HSS is ranked world #1 in orthopedics for a fourth consecutive year (2023). Founded in 1863, the Hospital has the lowest readmission rates in the nation for orthopedics, and among the lowest infection and complication rates. HSS was the first in New York State to receive Magnet Recognition for Excellence in Nursing Service from the American Nurses Credentialing Center five consecutive times. An affiliate of Weill Cornell Medical College, HSS has a main campus in New York City and facilities in New Jersey, Connecticut and in the Long Island and Westchester County regions of New York State, as well as in Florida. In addition to patient care, HSS leads the field in research, innovation and education. The HSS Research Institute comprises 20 laboratories and 300 staff members focused on leading the advancement of musculoskeletal health through prevention of degeneration, tissue repair and tissue regeneration. In addition, more than 200 HSS clinical investigators are working to improve patient outcomes through better ways to prevent, diagnose, and treat orthopedic, rheumatic and musculoskeletal diseases. The HSS Innovation Institute works to realize the potential of new drugs, therapeutics and devices. The HSS Education Institute is a trusted leader in advancing musculoskeletal knowledge and research for physicians, nurses, allied health professionals, academic trainees, and consumers in more than 165 countries. The institution is collaborating with medical centers and other organizations to advance the quality and value of musculoskeletal care and to make world-class HSS care more widely accessible nationally and internationally. . About Stamford Health Stamford Health is a non-profit independent health care system with more than 3,900 employees committed to caring for the community through a wide range of high-quality health and wellness services. Patients and their families receive expert, compassionate care through the system's 305-bed Stamford Hospital; Stamford Health Medical Group, with more than 40 offices in lower Fairfield County offering primary and specialty care; a growing number of ambulatory locations across the region; and support through the Stamford Hospital Foundation. Stamford Health is known for its expert, person-centered care through its many recognitions and partnerships. U.S. News & World Report has recognized Stamford Hospital as a High-Performing Hospital. The Leapfrog Group awarded Stamford Hospital an "A" for patient safety. The American Nurses Credentialing Center has granted Stamford Hospital Magnet Status, which recognizes superior patient care with the highest level of safety, quality, and patient satisfaction. Stamford Health is Planetree Gold-Certified for Excellence in Person-Centered Care and is a Certified™ Great Place to Work. Stamford Health is a major teaching affiliate of the Columbia University Vagelos College of Physicians and Surgeons and offers treatment and expertise from Columbia University Irving Medical Center's nationally recognized heart and neurosurgeons. Stamford Health and Hospital for Special Surgery (HSS) have created a premier center for specialty orthopedic care right in Stamford, Connecticut. Stamford Health's Carl & Dorothy Bennett Cancer Center has a robust collaboration with Dana-Farber Brigham Cancer Center. Dedicated to being the community's most trusted health care partner, Stamford Health puts patients first to build long-lasting relationships. For more information, visit StamfordHealth.org. Like us on Facebook and follow us on X, Instagram, YouTube, and LinkedIn. SOURCE Hospital for Special Surgery WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED